Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011589 · ClinicalTrials.gov registry record · Phase 1
Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)
A Phase 1 study, sponsored by M. Peter Marinkovich.
- Not yet
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07011589 is a Phase 1 study that has not yet begun recruiting, run by M. Peter Marinkovich. The registered enrollment target is 18 participants.
The verdict
NCT07011589, a Phase 1 study, has not yet begun recruiting, sponsored by M. Peter Marinkovich.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.
Interventions
- BIOLOGICAL Efgartigimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011589
The ClinicalTrials.gov registry entry for NCT07011589 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M. Peter Marinkovich, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efgartigimod is the first listed.
NCT07011589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07011589 about?
NCT07011589 is a clinical study titled "Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)". The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum. Fewer wounds, more rapidly...
What is the current status of trial NCT07011589?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-07. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07011589?
The interventions under investigation include: Efgartigimod (BIOLOGICAL).
Who is sponsoring clinical trial NCT07011589?
This trial is sponsored by M. Peter Marinkovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.